Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | RecQ helicase-like | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Giardia lamblia | U5 small nuclear ribonucleoprotein 200 kDa helicase, putative | RecQ helicase-like | 649 aa | 521 aa | 19.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Treponema pallidum | ATP-dependent DNA helicase | 0.0012 | 0.0381 | 0.5 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0024 | 1 | 1 |
Trichomonas vaginalis | DNA helicase recq, putative | 0.0024 | 1 | 0.5 |
Plasmodium falciparum | ATP-dependent DNA helicase Q1 | 0.0024 | 1 | 0.5 |
Schistosoma mansoni | DNA helicase recq5 | 0.0024 | 1 | 1 |
Echinococcus multilocularis | ATP dependent DNA helicase Q1 | 0.0024 | 1 | 0.5 |
Trypanosoma brucei | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0024 | 1 | 0.5 |
Plasmodium falciparum | ADP-dependent DNA helicase RecQ | 0.0024 | 1 | 0.5 |
Loa Loa (eye worm) | RecQ helicase | 0.0024 | 1 | 1 |
Echinococcus granulosus | ATP dependent DNA helicase Q5 | 0.0024 | 1 | 0.5 |
Trypanosoma cruzi | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0024 | 1 | 1 |
Echinococcus multilocularis | ATP dependent DNA helicase Q5 | 0.0024 | 1 | 0.5 |
Schistosoma mansoni | blooms syndrome DNA helicase | 0.0012 | 0.0381 | 0.0381 |
Giardia lamblia | Sgs1 DNA helicase, putative | 0.0024 | 1 | 0.5 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0024 | 1 | 1 |
Leishmania major | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0024 | 1 | 0.5 |
Echinococcus multilocularis | bloom syndrome protein | 0.0024 | 1 | 0.5 |
Plasmodium vivax | ADP-dependent DNA helicase RecQ, putative | 0.0012 | 0.0381 | 1 |
Schistosoma mansoni | DNA helicase recq1 | 0.0024 | 1 | 1 |
Brugia malayi | ATP-dependent DNA helicase, RecQ family protein | 0.0024 | 1 | 0.5 |
Loa Loa (eye worm) | ATP-dependent DNA helicase | 0.0024 | 1 | 1 |
Entamoeba histolytica | recQ family DNA helicase | 0.0012 | 0.0381 | 0.0381 |
Brugia malayi | Bloom's syndrome protein homolog | 0.0024 | 1 | 0.5 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0012 | 0.0381 | 0.0381 |
Trichomonas vaginalis | DNA helicase recq1, putative | 0.0024 | 1 | 0.5 |
Echinococcus granulosus | bloom syndrome protein | 0.0024 | 1 | 0.5 |
Echinococcus granulosus | ATP dependent DNA helicase Q1 | 0.0024 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 1 | 1 |
Trichomonas vaginalis | DNA helicase recq, putative | 0.0024 | 1 | 0.5 |
Entamoeba histolytica | recQ family helicase, putative | 0.0024 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0381 | 0.00000000841 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.7943 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1). (Class of assay: confirmatory) [Related pubchem assays: 594 (Rhodamine region spectral profiling screen), 593 (Fluorescein region spectral profiling screen), 2367 (Probe Development Summary for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)), 2353 (qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1))] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.